Quote this publication Share Print

COSENTYX (secukinumab), anti-interleukin-17A immunosuppressant

RHEUMATOLOGY - New indication
Opinions on drugs - Posted on Aug 23 2016

Reason for request

Inclusion

No clinical benefit demonstrated by comparison with anti-TNF therapy in the treatment of ankylosing spondylitis

  • COSENTYX has Marketing Authorisation for the treatment of active ankylosing spondylitis in adults in case of inadequate response to conventional treatment.
  • Given the lack of direct comparison of secukinumab to anti-TNF therapy and more significant long-term data with the latter, COSENTYX must be reserved as second line, after failure of anti-TNF therapy.

Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Contact Us

Évaluation des médicaments